Table 2.
Patient characteristics and clinical indicationsa
| All with HASTE (n = 257) |
Pre-FE HASTE (n = 121) |
Post-FE HASTE (n = 229) |
Pre- and post-FE HASTE (n = 93) |
|
|---|---|---|---|---|
| Age, y | 49 (16–67) | 39 (13–65) | 48 (16–67) | 44 (16–67) |
| Gender (female) | 118 (46%) | 52 (43%) | 95 (41%) | 40 (43%) |
| Pre-CMR creatinine (mg/dL) | 1.9 (1.2–2.9) | 1.9 (1.0–3.0) | 1.9 (0.99–2.8) | 1.7 (0.95–2.85) |
| Clinical indications | ||||
| Aneurysm /dissection | 18 (8%) | 6 (5%) | 18 (8%) | 6 (6%) |
| AVMs | 2 (1%) | 0 | 2 (1%) | 0 |
| CHD | 40 (16%) | 15 (12%) | 36 (16%) | 11 (12%) |
| Embolus /thrombus | 15 (6%) | 7 (6%) | 14 (6%) | 6 (6%) |
| Interventional planning | 28 (11%) | 16 (13%) | 26 (11%) | 14 (15%) |
| Mass | 19 (7%) | 13 (11%) | 19 (8%) | 13 (14%) |
| Other | 10 (4%) | 4 (3%) | 9 (4%) | 3 (3%) |
| Placenta | 4 (2%) | 4 (3%) | 4 (2%) | 4 (4%) |
| Post-renal transplant | 21 (8%) | 12 (10%) | 20 (9%) | 11 (12%) |
| Pre-renal transplant | 12 (5%) | 6 (5%) | 8 (3%) | 2 (2%) |
| Vascular mapping | 22 (9%) | 12 (10%) | 14 (6%) | 4 (4%) |
| Vascular thrombosis | 66 (26%) | 26 (21%) | 59 (26%) | 19 (20%) |
AVMs arteriovenous malformations, CHD congenital heart disease, CKD chronic kidney disease, eGFR estimated glomerular filtration rate, FE ferumoxytol enhanced, y years
aValues are reported as median and interquartile range or absolutes and frequencies